PMID- 33099742
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210319
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 12
IP  - 1
DP  - 2021 Jan
TI  - Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in 
      Patients with Type 2 Diabetes Mellitus.
PG  - 171-181
LID - 10.1007/s13300-020-00948-1 [doi]
AB  - INTRODUCTION: The aim of this analysis was to evaluate the efficacy of 
      lobeglitazone on albuminuria at 24 weeks of follow-up in patients with type 2 
      diabetes mellitus (T2DM) compared with pioglitazone using data from a randomized, 
      double-blinded phase III trial. METHODS: In the phase III trial, patients who 
      were inadequately controlled with metformin received 0.5 mg of lobeglitazone or 
      15 mg of pioglitazone for 24 weeks. Post hoc, exploratory analysis was used to 
      investigate mean changes from baseline in the urine albumin-creatinine ratio 
      (UACR) between the lobeglitazone (N = 104) and pioglitazone (N = 101) treatment 
      groups. RESULTS: After 24 weeks of treatment, UACR was slightly decreased in the 
      lobeglitazone group (- 4.3 mg/g creatinine [Cr]) compared to baseline and 
      slightly increased in the pioglitazone group (5.2 mg/g Cr), with no change in the 
      estimated glomerular filtration rate in either group; this difference was not 
      statistically significant (P = 0.476). The incidence of new-onset 
      microalbuminuria (2.4%) and the progression of albuminuria by > 1 stage (2.9%) in 
      the lobeglitazone group were lower than the respective values in the pioglitazone 
      group (6.8 and 6.1%, respectively). Of the patients in the lobeglitazone group, 
      50% exhibited regression to normoalbuminuria, compared to 39.3% of the patients 
      in the pioglitazone. In subjects in the lobeglitazone group with micro- and 
      macroalbuminuria, UACR tended to be more decreased and HbA1c was more reduced 
      compared to those with normoalbuminuria (P = 0.014). CONCLUSION: Lobeglitazone 
      had a tendency to improve albuminuria in patients with T2DM and had comparable 
      effects on albuminuria as pioglitazone which has demonstrated beneficial effects. 
      TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT01106131.
FAU - Kim, Kyung-Soo
AU  - Kim KS
AUID- ORCID: 0000-0002-7738-2284
AD  - Department of Internal Medicine, CHA Bundang Medical Center, CHA University 
      School of Medicine, Seongnam, Republic of Korea.
FAU - Hong, Sangmo
AU  - Hong S
AUID- ORCID: 0000-0002-8535-0565
AD  - Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang 
      University College of Medicine, Guri, Republic of Korea.
FAU - Ahn, Hong-Yup
AU  - Ahn HY
AD  - Department of Statistics, Dongguk University-Seoul, Seoul, Republic of Korea.
FAU - Park, Cheol-Young
AU  - Park CY
AUID- ORCID: 0000-0002-9415-9965
AD  - Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan 
      University School of Medicine, Seoul, Republic of Korea. cydoctor@chol.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT01106131
PT  - Journal Article
DEP - 20201024
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC7843821
OTO - NOTNLM
OT  - Albuminuria
OT  - Diabetes mellitus, type 2
OT  - Pioglitazone
OT  - Thiazolidinediones
EDAT- 2020/10/26 06:00
MHDA- 2020/10/26 06:01
PMCR- 2020/10/24
CRDT- 2020/10/25 20:16
PHST- 2020/09/11 00:00 [received]
PHST- 2020/10/10 00:00 [accepted]
PHST- 2020/10/26 06:00 [pubmed]
PHST- 2020/10/26 06:01 [medline]
PHST- 2020/10/25 20:16 [entrez]
PHST- 2020/10/24 00:00 [pmc-release]
AID - 10.1007/s13300-020-00948-1 [pii]
AID - 948 [pii]
AID - 10.1007/s13300-020-00948-1 [doi]
PST - ppublish
SO  - Diabetes Ther. 2021 Jan;12(1):171-181. doi: 10.1007/s13300-020-00948-1. Epub 2020 
      Oct 24.